Shares of Replimune Group rose after the biotechnology company said its underwritten offering of 9.7 million shares was priced at $12.06 a share.
The stock was up 15% to $13.81 in recent trading, and has risen 42% since the start of the year.
Proceeds from the offering are expected to be approximately $150 million.
The offering is expected to close Aug. 11.